CD44, CD24, CD133 and CD26 were previously identified as CSC surface markers and as indicators of higher tumorigenic capability or with an invasive potential for CRC (King et al., 2012; O'Brien et al., 2007; Pang et al., 2010; Yeung et al., 2010). This evidence concerns the gene CD44 and colorectal carcinoma.